Clinical advancements in the field of urology are featured in the news media every day. This section provides patients and physicians with the most up-to-date information on recent urologic advancements around the world.
* Please Note - TUCC does not necessarily advocate any of the treatment methods listed in the articles below. This news feed is provided as a resource for those interested in the latest urologic research occurring around the world.
Prostate-specific antigen (PSA) screening is associated with a lasting reduction in prostate cancer mortality, with increased effect at 13 years compared with nine or 11 years, according to a study published online in The Lancet.
Prostate cancer (PCa) patients with a BRCA2 mutation are more likely to die from the malignancy than those without the mutation, researchers reported online in the British Journal of Cancer.
Diagnoses of late-stage prostate cancer among younger men are on a surprising increase, with a nearly sixfold rise in diagnoses over two decades — too much of an increase to link solely to better screening, according to a team of researchers at the University of Michigan Comprehensive Cancer Center.
Some of these cases turn out to be very aggressive and these men can present with cancer that has already spread to lymph nodes and bone.
Avella Specialty Pharmacy, in collaboration with the American Liver Foundation and Denver Colorado AIDS Project, will offer free Hepatitis screenings for individuals considered high risk at its Denver-based facility on July 28th in support of World Hepatitis Day. Hepatitis C can be detected through a simple blood test that identifies antibodies to the virus. Early detection of the Hepatitis C Virus (HCV) is critical since many individuals that have the condition exhibit no symptoms and don’t realize they are infected. Early detection can also help prevent serious complications from this disease including liver damage, cirrhosis and even liver cancer.
Adding the chemotherapy drug docetaxel to standard hormone-depleting therapy may extend the lives of men with advanced prostate cancer, a new study finds.
The study was to be presented Sunday in Chicago at the annual meeting of the American Society of Clinical Oncology (ASCO).
A single type of cell in the lining of the bladder is responsible for most cases of invasive bladder cancer, according to researchers at the Stanford University School of Medicine.
Their study, conducted in mice, is the first to pinpoint the normal cell type that can give rise to invasive bladder cancers. It's also the first to show that most bladder cancers and their associated precancerous lesions arise from just one cell, and explains why many human bladder cancers recur after therapy.
Low testosterone levels may indicate disease worsening in men diagnosed with low-risk prostate cancer who are being evaluated by active surveillance, according to a new study by Pontificia Universidad Católica de Chile in Santiago, Chile and Beth Israel Deaconess Medical Center in Boston. The results were published in BJU International.
Of a total of 154 men undergoing active surveillance followed for a median of 38 months, 35% (54 men) progressed to active treatment. All of the men were initially diagnosed with low-risk prostate cancer. Those men who transitioned to active treatment had significantly lower free testosterone levels compared with those who continued to have classified low-risk disease (P = .03). The median age of the men was 62, and all were enrolled into the prospective cohort between 2000 and 2012.
Novel noninvasive technique successfully discriminates between prostate cancer and benign disease in proof of principle study, paving the way for easy and early diagnosis, reports the Journal Of Urology
Three professional medical societies and a highly distinguished international group of over 130 scientists and concerned physicians have petitioned the Journal of the American Medical Association to retract the article that precipitated recent concerns regarding cardiovascular risks with testosterone therapy. In a letter addressed to the editor-in-chief of JAMA, Dr. Howard Bauchner, the group cites "gross data mismanagement," rendering the article "no longer credible."
Patients treated with a newer, faster type of radiotherapy, called stereotactic body radiation therapy (SBRT/Cyberknife), also have higher rates of urinary complications, according to a new study published in the Journal of Clinical Oncology.
Six months following treatment, 15.6% of patients treated with SBRT had a genitourinary toxicity compared with 12.6% of those treated with IMRT. At 24 months after treatment initiation, patients treated with SBRT had increased side effects, including urethritis, urinary incontinence, and urinary obstruction. Of patients treated with SBRT, 43.9% had a genitourinary toxicity compared with 36.3% of those treated with IMRT.
SBRT is beginning to replace the older standard approach, intensity-modulated radiation therapy (IMRT). However, the new study by James B. Yu, MD, of the Yale School of Medicine and Yale Cancer Center, and colleagues at the Cancer Outcomes, Public Policy, and Effectiveness Research (COPPER) Center at Yale Cancer Center shows that SBRT is associated with increased toxicity that offsets the savings of using this newer form of radiotherapy.
TUCC is contracted with all major insurance companies. We look forward to providing you with clinically advanced, compassionate urologic care.